Tekla Capital Management’s Travere Therapeutics TVTX Stock Holding History

Tekla Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-418,520	Closed	-$9.41M	–	181
2023 Q1	$9.41M	Hold	418,520	–	–	0.36%	58
2022 Q4	$8.8M	Buy	418,520 +170,842	+69%	+$3.62M	0.33%	60
2022 Q3	$6.1M	Hold	247,678	–	–	0.25%	71
2022 Q2	$6M	Hold	247,678	–	–	0.24%	81
2022 Q1	$6.38M	Buy	247,678 +34,809	+16%	+$924K	0.22%	84
2021 Q4	$6.61M	Hold	212,869	–	–	0.21%	89
2021 Q3	$5.16M	Hold	212,869	–	–	0.17%	105
2021 Q2	$3.11M	Hold	212,869	–	–	0.1%	141
2021 Q1	$5.32M	Buy	+212,869	New	+$5.88M	0.18%	113
2017 Q3	–	Sell	-167,949	Closed	-$3.26M	–	160
2017 Q2	$3.26M	Hold	167,949	–	–	0.12%	97
2017 Q1	$3.1M	Hold	167,949	–	–	0.12%	95
2016 Q4	$3.18M	Sell	167,949 -162,000	-49%	-$3.31M	0.14%	88
2016 Q3	$7.38M	Hold	329,949	–	–	0.28%	72
2016 Q2	$5.88M	Hold	329,949	–	–	0.24%	82
2016 Q1	$4.51M	Hold	329,949	–	–	0.19%	92
2015 Q4	$6.37M	Buy	+329,949	New	+$6.59M	0.23%	81

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tekla Capital Management's TVTX Position: Q2 2023 in Review

Tekla Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 418,520 shares — an estimated $9.41M sold.

Tekla Capital Management first reported a position in TVTX in Q4 2015 and held it in 16 quarters. The position peaked at $9.41M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Tekla Capital Management reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Tekla Capital Management sold 418,520 Travere Therapeutics shares in Q2 2023, an estimated $9.41M.
Tekla Capital Management first reported a position in Travere Therapeutics in Q4 2015 and held it in 16 quarters.
Tekla Capital Management's Travere Therapeutics position peaked at $9.41M in Q1 2023.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.